SEC Form 4 · accession 0001615774-18-003217
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Rapp
10% Owner
Period of report
Mar 22, 2018
Accepted (ET)
May 2, 2018 · 5:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 2, 2018 | P | 15,000 | $10.463 | A | 1,494,115 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $10.50, inclusive. The reporting person undertakes to provide to Zynerba, any security holder of Zynerba, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM.